Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market (Drug Class - Lipopeptide, Oxazolidinone, Cephalosporin, Tetracycline, Lipoglycopeptide, Folate Antagonist; Route of Administration - Oral and Parenteral; Distribution Channel - Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

The global methicillin-resistant staphylococcus aureus (MRSA) drugs market is estimated to attract notable expansion opportunities in the upcoming years. This growth can be attributed to many factors including increasing occurrence of the antibiotic resistant strains development among population of all age groups.

Staphylococcus aureus refers to bacteria generally seen on the skin or nose of healthy individuals. Methicillin-resistant staphylococcus aureus (MRSA) can be defined as a staphylococcus aureus type, which shows resistance to beta-lactam antibiotic named methicillin.

Some of the prominent players in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market include The Medicines Company, Basilea Pharmaceutica Ltd., Allergan, Merck & Co., Inc., Pfizer, Inc., and Theravance Biopharma. Presence of several prominent companies makes the competitive landscape of the market highly intense, which encourages enterprises to use organic as well as inorganic strategies in order to stay ahead in the competition.

Leading organizations in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market are investing heavily in the clinical trials and R&D projects, which are concentrated on the formulation of exclusive drug molecules. Moreover, many players are focusing on the launch of generic drugs against the presently available products that have lost the patent exclusivity.

The COVID-19 pandemic has shown impact major industries including the global methicillin-resistant staphylococcus aureus (MRSA) drugs market. Companies have developed several policies and strategies in order to address this issue and ensure consistent revenue generation.

Several companies from the North America region, specifically the U.S., are increasing investments toward the R&D projects, which are focused on the development of screening tools for MRSA infection. This factor has helped in making North America as leading market region in the methicillin-resistant staphylococcus aureus (MRSA) drugs market. Moreover, Asia Pacific is expected to emerge as fastest growing region for the market in the years to come.

Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market: Snapshot

Staphylococcus aureus is a bacteria commonly found on nose or skin of healthy people. MRSA i.e., methicillin-resistant staphylococcus aureus, is thus a type of staphylococcus aureus that is resistant to beta-lactam antibiotic called methicillin. MRSA strains do not respond to methicillin treatment. Around 1% of the population carrying staphylococcus aureus on their nose or skin are infected by MRSA. The infection causes skin and tissue infection, and is transmitted by direct skin-to-skin contact. Global MRSA drugs market accounted for a revenue of US$ 2,967.0 Mn in 2016, and is estimated to reach the value of US$ 3,908.2 Mn by the end of 2025, reflecting a CAGR of 3.2% during the forecast period.

mrsa-drugs-market.jpg

According to CDC, two in every 100 people carry MRSA. Prolonged stay of patients in long-term health care facilities is a major factor giving rise to a serious issue of surplus MRSA infections. According to the Healthcare Cost & Utilization Project (HCUP), a family of health care databases in the U.S., the rate of deaths of hospitalized patients caused by MRSA infections is higher than non-hospitalized patients (4.7% vs. 2.1% respectively). Improved screening of antibiotic resistant strains of bacteria by using technologically advanced diagnostic tools, and upsurge in the consumption of antibiotics across the globe are the major factors expected to fuel the growth of global MRSA drugs market during the forecast period. Key companies are entering the distribution agreements with the emerging regional players to improve the accessibility of their anti-MRSA agents. Basilea Pharmaceutica, one of the leading MRSA drugs manufacturer, entered into a license agreement for its anti-MRSA antibiotic Zevtera (ceftobiprole) with Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (China). Such key strategies being adopted by the manufacturers is expected to propel the growth of MRSA drugs market during the forecast period. There is significant unmet need for the MRSA infection, which create huge opportunities for existing players and new entrants in the market. Also adopting the strategies such as establishing commercial partnerships for co-development and commercialization of anti-MRSA agents provide scope for opportunities in the global MRSA drugs market. However, lack of systematic surveillance for MRSA infection in developing countries is likely to hamper the growth of MRSA drugs market during 2017-2025.

The global MRSA drugs market is segmented on the basis of drug class, route of administration, and distribution channel. On the basis of drug class, the global MRSA drugs market is classified as lipopeptide, oxazolidinone, cephalosporin, tetracycline, lipoglycopeptide, folate antagonists, and others. Lipopeptide drug class held the maximum market share in 2016 in terms of revenue, owing to the established market for lipopeptides such as Daptomycin owing to efficient distribution by manufacturers and distributors across the globe. Tetracycline and Lipoglycopeptide are likely to register moderate CAGR by 2025. However, others drug class segment, which is comprised of fluoroquinolones, streptogramins, etc., is anticipated to witness significant CAGR during the forecast period, which is attributable to the rising prevalence of MRSA infection in community settings of the developing countries. Based on the route of administration, the global MRSA market is segmented into oral and parenteral. Parenteral segment accounted for highest revenue in 2016, and is expected to continue to lead the market during 2017-2025. The estimated dominance of the segment is attributed to its preference as a first line of therapy in the MRSA treatment. In terms of distribution channel, the global MRSA drugs market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. Rising number of multispecialty hospitals worldwide, and improved supply of the generic MRSA drugs in the hospital pharmacies across the globe are the major factors for the dominance of hospital pharmacy segment in terms of revenue in 2016. However, online pharmacy is expected to grow at relatively significant CAGR during 2017-2025, due to availability of antibiotics on the online platform with attractive offers and discounts.

Geographically, global MRSA drugs market is divided into five major regions, which are North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounted for maximum revenue in 2016, owing to the strategic presence of key antibiotic manufacturing companies in the U.S. North America is estimated to remain dominant throughout the forecast period, which is attributable to the increasing investment by key players in the R&D of novel drug molecules against MRSA infection. However, rising awareness about the antibiotic resistant bacterial infections in the emerging economies of Asian countries, and rising incidence of hospital-acquired MRSA infection in India & China are the major factors for the estimated growth of Asia Pacific with relatively significant CAGR by 2025.

The prominent players operating in the global MRSA Drugs Market are Basilea Pharmaceutica Ltd., The Medicines Company, Theravance Biopharma, Allergan, Merck & Co., Inc., and Pfizer, Inc. Investing in the R&D and clinical trials of unique drug molecules, and introducing the generic drugs against the existing products which have lost the patent exclusivity are the major strategies being adopted by key manufacturers to stay ahead in the rising competition.

The Global MRSA drugs Market has been segmented as given below:

Drug Class

  • Lipopeptide
  • Oxazolidinone
  • Tetracycline
  • Cephalosporin
  • Lipoglycopeptide
  • Folate Antagonist
  • Others

Administration

  • Oral
  • Parenteral

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • India
    • China
    • Japan
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Rest of Middle East & Africa

Frequently Asked Questions

What is the total market worth of methicillin-resistant staphylococcus aureus (MRSA) drugs market?

Methicillin-resistant staphylococcus aureus (MRSA) drugs market to reach over US$ 3.9 Bn by 2025

What is the anticipated CAGR of the methicillin-resistant staphylococcus aureus (MRSA) drugs market in the forecast period?

Methicillin-resistant staphylococcus aureus (MRSA) drugs market is projected to register CAGR of over 3.2% from 2017 to 2025

What are the key driving factors for the growth of the methicillin-resistant staphylococcus aureus (MRSA) drugs market?

Methicillin-resistant staphylococcus aureus (MRSA) drugs market is driven by rising incidence of the development of antibiotic resistant strains among all age groups

Which region is expected to project the highest market share in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market?

Asia Pacific accounted for a major share of the global methicillin-resistant staphylococcus aureus (MRSA) drugs market

Who are the key players in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market?

Key players in the global methicillin-resistant staphylococcus aureus (MRSA) drugs market include The Medicines Company, Basilea Pharmaceutica Ltd., Allergan, Merck & Co., Inc., Pfizer, Inc., and Theravance Biopharma

    1. Preface
         1.1. Market Definition and Scope
         1.2. Market Segmentation
         1.3. Key Research Objectives
         1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary : Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market

    4. Market Overview
         4.1. Drug Class Overview
         4.2. Global MRSA Drugs Market Outlook

    5. Market Dynamics
         5.1. Drivers
         5.2. Restraints
         5.3. Opportunities

    6. Epidemiological Assessment of Methicillin-resistant Staphylococcus Aureus (MRSA)

    7. MRSA Drugs: Pipeline Analysis

    8. MRSA Drugs Market: Competitive Landscape of Key Players

    9. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Drug Class 
         9.1. Introduction & Definition
         9.2. Key Findings / Developments
         9.3. Market Value Forecast By Drug Class, 2015–2025
                9.3.1. Lipopeptide
                9.3.2. Oxazolidinone
                9.3.3. Cephalosporin
                9.3.4. Tetracycline
                9.3.5. Lipoglycopeptide
                9.3.6. Folate Antagonist
                9.3.7. Others
         9.4. Market Attractiveness By Drug Class 
         9.5 Key Trends

    10. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Route of Administration 
         10.1. Introduction & Definition
         10.2. Key Findings / Developments
         10.3. Market Value Forecast By Route of Administration, 2015–2025
                10.3.1. Oral
                10.3.2. Parenteral
         10.4. Market Attractiveness By Route of Administration 
         10.5. Key Trends

    11. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Distribution Channel 
         11.1. Introduction & Definition
         11.2. Key Findings / Developments
         11.3. Market Value Forecast By Distribution Channel, 2015–2025
                11.3.1. Hospital Pharmacy
                11.3.2. Retail Pharmacy
                11.3.3. Online Pharmacy
         11.4. Market Attractiveness By Distribution Channel 
         11.5 Key Trends

    12. Global Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecasts, By Region
         12.1. Key Findings
         12.2. Market Value Forecast By Region
                12.2.1. North America 
                12.2.2. Europe 
                12.2.3. Asia Pacific 
                12.2.4. Latin America 
                12.2.5. Middle East & Africa 
         12.3. Market Attractiveness By Country/Region

    13. North America Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
         13.1. Introduction
                13.1.1. Key Findings
         13.2. Market Value Forecast By Drug Class, 2015–2025
                13.2.1. Lipopeptide
                13.2.2. Oxazolidinone
                13.2.3. Cephalosporin
                13.2.4. Tetracycline
                13.2.5. Lipoglycopeptide
                13.2.9. Folate Antagonist
                13.2.7. Others
         13.3. Market Value Forecast By Route of Administration, 2015–2025
                13.3.1. Oral
                13.3.2. Parenteral
         13.4. Market Value Forecast By Distribution Channel, 2015–2025
                13.4.1. Hospital Pharmacy
                13.4.2. Retail Pharmacy
                13.4.3. Online Pharmacy
         13.5. Market Value Forecast By Country, 2015–2025
                13.5.1. U.S.
                13.5.2. Canada
         13.6. Market Attractiveness Analysis 
                13.6.1. By Drug Class 
                13.6.2. By Route of Administration 
                13.6.3. By Distribution Channel 
                13.6.4. By Country

    14. Europe Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
         14.1.Introduction
                14.1.1. Key Findings
         14.2.Market Value Forecast By Drug Class, 2015–2025
                14.2.1. Lipopeptide
                14.2.2. Oxazolidinone
                14.2.3. Cephalosporin
                14.2.4. Tetracycline
                14.2.5. Lipoglycopeptide
                14.2.6. Folate Antagonist
                14.2.7. Others
         14.3.Market Value Forecast By Route of Administration, 2015–2025
                14.3.1. Oral
                14.3.2. Parenteral
         14.4.Market Value Forecast By Distribution Channel, 2015–2025
                14.4.1. Hospital Pharmacy
                14.4.2. Retail Pharmacy
                14.4.3. Online Pharmacy
         14.5.Market Value Forecast By Country, 2015–2025
                14.5.1. Germany
                14.5.2. U.K.
                14.5.3. France
                14.5.4. Spain
                14.5.5. Italy
                14.5.6. Russia
                14.5.7. Rest of Europe
         14.6.Market Attractiveness Analysis 
                14.6.1. By Drug Class 
                14.6.2. By Route of Administration 
                14.6.3. By Distribution Channel 
                14.6.4. By Country

    15. Asia Pacific Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
         15.1.Introduction
                15.1.1. Key Findings
         15.2.Market Value Forecast By Drug Class, 2015–2025
                15.2.1. Lipopeptide
                15.2.2. Oxazolidinone
                15.2.3. Cephalosporin
                15.2.4. Tetracycline
                15.2.5. Lipoglycopeptide
                15.2.6. Folate Antagonist
                15.2.7. Others
         15.3.Market Value Forecast By Route of Administration, 2015–2025
                15.3.1. Oral
                15.3.2. Parenteral
         15.4.Market Value Forecast By Distribution Channel, 2015–2025
                15.4.1. Hospital Pharmacy
                15.4.2. Retail Pharmacy
                15.4.3. Online Pharmacy
         15.5.Market Value Forecast By Country, 2015–2025
                15.5.1. China
                15.5.2. Japan
                15.5.3. India
                15.5.4. Australia & New Zealand
                15.5.5. Rest of Asia Pacific
         15.6.Market Attractiveness Analysis 
                15.6.1. By Drug Class 
                15.6.2. By Route of Administration 
                15.6.3. By Distribution Channel 
                15.6.4. By Country

    16. Latin America Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
         16.1.Introduction
                16.1.1. Key Findings
         16.2.Market Value Forecast By Drug Class, 2015–2025
                16.2.1. Lipopeptide
                16.2.2. Oxazolidinone
                16.2.3. Cephalosporin
                16.2.4. Tetracycline
                16.2.5. Lipoglycopeptide
                16.2.6. Folate Antagonist
                16.2.7. Others
         16.3.Market Value Forecast By Route of Administration, 2015–2025
                16.3.1. Oral
                16.3.2. Parenteral
         16.4.Market Value Forecast By Distribution Channel, 2015–2025
                16.4.1. Hospital Pharmacy
                16.4.2. Retail Pharmacy
                16.4.3. Online Pharmacy
         16.5.Market Value Forecast By Country, 2015–2025
                16.5.1. Brazil
                16.5.2. Mexico
                16.5.3. Rest of Latin America
         16.6.Market Attractiveness Analysis 
                16.6.1. By Drug Class 
                16.6.2. By Route of Administration 
                16.6.3. By Distribution Channel 
                16.6.4. By Country

    17. Middle East & Africa Methicillin-resistant Staphylococcus Aureus (MRSA) Drugs Market Analysis and Forecast
         17.1.Introduction
                17.1.1. Key Findings
         17.2.Market Value Forecast By Drug Class, 2015–2025
                17.2.1. Lipopeptide
                17.2.2. Oxazolidinone
                17.2.3. Cephalosporin
                17.2.4. Tetracycline
                17.2.5. Lipoglycopeptide
                17.2.6. Folate Antagonist
                17.2.7. Others
         17.3.Market Value Forecast By Route of Administration, 2015–2025
                17.3.1. Oral
                17.3.2. Parenteral
         17.4.Market Value Forecast By Distribution Channel, 2015–2025
                17.4.1. Hospital Pharmacy
                17.4.2. Retail Pharmacy
                17.4.3. Online Pharmacy
         17.5.Market Value Forecast By Country, 2015–2025
                17.5.1. GCC Countries
                17.5.2. South Africa
                17.5.3. Israel
                17.5.4. Rest of Middle East & Africa
         17.6.Market Attractiveness Analysis 
                17.6.1. By Drug Class 
                17.6.2. By Route of Administration 
                17.6.3. By Distribution Channel 
                17.6.4. By Country

    18. Competition Landscape
         18.1.Market Player – Competition Matrix (By Tier and Size of companies)
         18.2.Market Share Analysis By Company (2016)
         18.3. Company Profiles
                18.5.1. Basilea Pharmaceutica Ltd.
                          18.3.1.1. Overview
                          18.3.1.2.Financials
                          18.3.1.3.Recent Developments
                          18.3.1.4.SWOT Analysis
                          18.3.1.5.Strategic Overview
                18.3.2. The Medicines Company
                          18.3.2.1. Overview
                          18.3.2.2.Financials
                          18.3.2.3.Recent Developments
                          18.3.2.4.SWOT Analysis
                          18.3.2.5.Strategic Overview
                18.3.3. Theravance Biopharma
                          18.3.3.1. Overview
                          18.3.3.2.Financials
                          18.3.3.3.Recent Developments
                          18.3.3.4.SWOT Analysis
                          18.3.3.5.Strategic Overview
                18.3.4. Allergan
                          18.3.4.1. Overview
                          18.3.4.2.Financials
                          18.3.4.3.Recent Developments
                          18.3.4.4.SWOT Analysis
                          18.3.4.5.Strategic Overview
                18.3.5. Merck & Co., Inc.
                          18.3.5.1. Overview
                          18.3.5.2.Financials
                          18.3.5.3.Recent Developments
                          18.3.5.4.SWOT Analysis
                          18.3.5.5.Strategic Overview
                18.3.6. Pfizer, Inc.
                          18.3.6.1. Overview
                          18.3.6.2.Financials
                          18.3.6.3.Recent Developments
                          18.3.6.4.SWOT Analysis
                          18.3.6.5.Strategic Overview

    List of Tables

    Table 01 Global MRSA infection Prevalence (%), 2015
    Table 02 Global MRSA infection Prevalence (%), 2015
    Table 03 Global MRSA infection Prevalence (%), 2015
    Table 04 MRSA Drugs: Pipeline Snapshot, 2016
    Table 05 MRSA Drugs: Pipeline Snapshot, 2016
    Table 06 MRSA Drugs: Competitive Landscape
    Table 07 Global MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 08 Global MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 09 Global MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 10 Global MRSA Drugs Market Size (US$ Mn) Forecast, by Region, 2015–2025
    Table 11 North America MRSA Drugs Market Size (US$ Mn) Forecast, by Country, 2015–2025
    Table 12 North America MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 13 North America MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 14 North America MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 15 Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 16 Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 17 Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 18 Europe MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 19 Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 20 Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 21 Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 22 Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 23 Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 24 Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 25 Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 26 Latin America MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025
    Table 27 Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Country/Sub-region, 2015–2025
    Table 28 Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2015–2025
    Table 29 Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2015–2025
    Table 30 Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2015–2025

    List of Figures

    Fig. 01 Global MRSA Drugs Market Size (US$ Mn) and Distribution (%) by Geography, 2017 and 2025
    Fig. 02 Global MRSA Drugs Market Value Share, by Drug Class (2016)
    Fig. 03 Global MRSA Drugs Market Value Share, by Route of Administration (2016)
    Fig. 04 Global MRSA Drugs Market Value Share, by Distribution Channel (2016)
    Fig. 05 Global MRSA Drugs Market Value Share, by Region (2016)
    Fig. 06 Key Manufacturers: Comparison Analysis
    Fig. 07 Global MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
    Fig. 08 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lipopeptide, 2015–2025
    Fig. 09 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Oxazolidinone, 2015–2025
    Fig. 10 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Cephalosporin, 2015–2025
    Fig. 11 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Tetracycline, 2015–2025
    Fig. 12 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Folate Antagonist, 2015–2025
    Fig. 13 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Other Drug Classes, 2015–2025
    Fig. 14 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%) Forecast, by Lipoglycopeptide, 2015–2025
    Fig. 15 Global MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
    Fig. 16 Global MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
    Fig. 17 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Oral Route of Administration, 2015–2025
    Fig. 18 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Parenteral Route of Administration, 2015–2025
    Fig. 19 Global MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
    Fig. 20 Global MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Fig. 21 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacy, 2015–2025
    Fig. 22 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacy, 2015–2025
    Fig. 23 Global MRSA Drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacy, 2015–2025
    Fig. 24 Global MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
    Fig. 25 Global MRSA Drugs Market Value Share, by Region, 2017 and 2025
    Fig. 26 Global MRSA Drugs Market Attractiveness, by Region, 2017–2025
    Fig. 27 North America MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
    Fig. 28 North MRSA Drugs Market Attractiveness, by Country, 2017–2025
    Fig. 29 North America MRSA Drugs Market Value Share, by Country, 2017 and 2025
    Fig. 30 North America MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
    Fig. 31 North America MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
    Fig. 32 North America MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
    Fig. 33 North America MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
    Fig. 34 North America MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Fig. 35 North America MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
    Fig. 36 Europe MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
    Fig. 37 Europe MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
    Fig. 38 Europe MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
    Fig. 39 Europe MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
    Fig. 40 Europe MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
    Fig. 41 Europe MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
    Fig. 42 Europe MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
    Fig. 43 Europe MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Fig. 44 Europe MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
    Fig. 45 Asia Pacific MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
    Fig. 46 Asia Pacific MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
    Fig. 47 Asia Pacific MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
    Fig. 48 Asia Pacific MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
    Fig. 49 Asia Pacific MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
    Fig. 50 Asia Pacific MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
    Fig. 51 Asia Pacific MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
    Fig. 52 Asia Pacific MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Fig. 53 Asia Pacific MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
    Fig. 54 Latin America MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
    Fig. 55 Latin America MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
    Fig. 56 Latin America MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
    Fig. 57 Latin America MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
    Fig. 58 Latin America MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
    Fig. 59 Latin America MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
    Fig. 60 Latin America MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
    Fig. 61 Latin America MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Fig. 62 Latin America MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
    Fig. 63 Middle East & Africa MRSA Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth Projection (%), 2015–2025
    Fig. 64 Middle East & Africa MRSA Drugs Market Attractiveness, by Country/Sub-region, 2017–2025
    Fig. 65 Middle East & Africa MRSA Drugs Market Value Share, by Country/Sub-region, 2017 and 2025
    Fig. 66 Middle East & Africa MRSA Drugs Market Value Share, by Drug Class, 2017 and 2025
    Fig. 67 Middle East & Africa MRSA Drugs Market Attractiveness, by Drug Class, 2017–2025
    Fig. 68 Middle East & Africa MRSA Drugs Market Value Share, by Route of Administration, 2017 and 2025
    Fig. 69 Middle East & Africa MRSA Drugs Market Attractiveness, by Route of Administration, 2017–2025
    Fig. 70 Middle East & Africa MRSA Drugs Market Value Share, by Distribution Channel, 2017 and 2025
    Fig. 71 Middle East & Africa MRSA Drugs Market Attractiveness, by Distribution Channel, 2017–2025
    Fig. 72 Global MRSA Drugs Market Share, by Company, 2016

Copyright © Transparency Market Research, Inc. All Rights reserved